10x Science built a platform that uses chemistry-based algorithms and AI agents to interpret complex mass spectrometry data, speeding up protein characterization for drug development. Backed by a $4.8 million seed round, it helps biotechs and pharma quickly validate AI-generated treatment candidates. The startup plans to refine its models and expand offerings by integrating broader cellular data.

• 10x Science raised a $4.8M seed round led by Initialized Capital to build AI that interprets mass spectrometry data for drug candidate validation, addressing the bottleneck created by AI protein-folding tools flooding pipelines with candidates.
• Its platform is fully traceable rather than a black box, which matters for regulatory compliance—unlike prior tools that over-promised or failed on complex molecules.
• Early users like Rilas Technologies report it shaves weeks off workflows, with the AI accurately identifying proteins by name and pulling sequences from public databases.
• Long-term plan is to layer cellular data on top of protein structure to create "molecular intelligence," positioning it as a potential go-to analytics engine for AI-driven drug development.